US Stock MarketDetailed Quotes
EVLO Evelo Biosciences
- 0.050
- +0.006+13.64%
15min DelayClose May 10 16:00 ET
949.14KMarket Cap-5P/E (TTM)
0.060High0.044Low48.34KVolume0.044Open0.044Pre Close2.59KTurnover0.55%Turnover RatioLossP/E (Static)18.98MShares13.93052wk High-0.04P/B443.00KFloat Cap0.02852wk Low--Dividend TTM8.86MShs Float398.566Historical High--Div YieldTTM36.36%Amplitude0.028Historical Low0.053Avg Price1Lot Size
About Evelo Biosciences Company
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
Company Profile
SymbolEVLO
Company NameEvelo Biosciences
Listing DateMay 9, 2018
Issue Price16.00
Founded2014
CEOMr. Craig R. Jalbert
MarketPink Market
Employees66
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressOne Kendal Square, 600/700,Suite 7-201
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-617-577-0300
Websitehttp://www.evelobio.com
Company Executives
- Name
- Position
- Salary
- Craig R. Jalbert
- President, Chief Executive Officer, Director, Corporate Secretary, Principal Accounting Officer and Principal Financial Officer
- --
- Mark D. Plinio
- Chief Commercial Officer
- --
- Mark Bodmer
- Chief Scientific Officer and President, Research and Development
- --
- Duncan McHale
- Chief Medical Officer
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
